Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab

Onkologie

Volumn 28, Issue 2, 2005, Pages 95-97

  Stemmler, Hans Joachim ^a   Stieber, Petra ^a   Lässig, Dorit ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Breast cancer, metastatic; Chemotherapy; HER2; HER2 shed antigen; Trastuzumab; Vinorelbine

Indexed keywords

CA 15-3 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; NAVELBINE; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ADULT; ARTICLE; BONE METASTASIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; LIVER METASTASIS; NEEDLE BIOPSY; SCORING SYSTEM; SIDE EFFECT;

ADENOCARCINOMA; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 14244251138     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082803     Document Type: Article

References (13)

1. McKeage K, Perry CM: Trastuzumab. Drugs 2002; 62:209-243.
2. Slamon DJ, Leyland-Jones, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2. N Engl J Med 2001;344:783-792.
3. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-2895.
4. Jahanzeb M, Mortimer JE, Yunus F, Irvin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002;7:410-417.
5. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G. Patterns of HER2/neu amplification in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-1146.
6. Gancberg D, DiLeo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-1043.
7. Durbecq V, DiLeo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D: Comparison of topoisomerase Iialpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003;77:199-204.
8. Cardoso F, DiLeo A, Larsimont D. Gancberg D, Rouas G, Dolci S, Ferreira F, Paesmans M, Piccart M: Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001;12:615-620.
9. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-140.
10. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R: Assessment of HER2 status in breast cancer: Why, when and how? Eur J Cancer 2000;36:170-176.
11. Lüftner D, Dilk H, Henschke P, Geppert R, Dietel M, Stein H, Wernecke K, Possinger K, Heine B: Concordance of HER-2/neu expression of primary breast carcinomas and their metachronous distant metastases: Results of a 10 year retrospective search in two university institutes of pathology. Eur J Cancer 2004;2 abstr #163.
12. Domenech GH, Vogel CL: A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2001;2:113-128.
13. Vogel CL, Cobleigh MA, Tripathy D Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.